Excellently written #CLML article about myeloma treatment in South Asia. 70% of #MMsm expenditures in 🇮🇳 🇵🇰 🇱🇰 🇧🇩 et al paid out of pocket by pts. Over half of public institutions don't have access to FLC testing, let alone SPEP... We have work to do! https://t.co/qvTdaYqRlX

Much awaited Hemat focused NGS Workshop at PGI, Chandigarh on Sept 25–26, 2025— covering library prep, reporting guidelines, platform demos, and bioinformatics pipelines! Register now; seats limited to the first 50 participants. Scan & pay #NGS @drssreejesh @DrPMPGI

Announcing #ISHG2026 — the 50th Annual Meeting of the Indian Society of Human Genetics, hosted by Hemat/Paed/CHMO depts PGIMER Chandigarh, 5–7 Feb 2026. Save the dates! Info: ishg2026@gmail.com #Genomics #HumanGenetics @drssreejesh @DrPMPGI @drpulkitrastogi

https://t.co/HtOPEyBZMA

Our recent publication on Targeted RNAseq in B-ALL. https://t.co/QqzFMkNtOE @DrPMPGI @Charanpreet_14 @drpulkitrastogi @DrGPrakash @drsharmapgi @ManuJamwal25 @Agilent #Leukemia #RNAseq #hematology #Bioinformatics

This is directed at the authors, editors, and administrators of the WHO Blue Books: 1️⃣ If a chapter relies on genetic testing unavailable to >80% of the world, it serves no one but those who already know the disease. Rewrite it. 2️⃣ If you plan to change nomenclature, ask: Does

The vision and the visionary. Prof @DrPMPGI has excellently conceived and lead a unique initiative in India to advance field of multiple myeloma research and care. Kudos! @IndMyAcGp #Image2025

Dear @drsharmapgi @drkunalsehgal @KBommannan @DrArunCMC @PrashantTembha1 @Thulas31081987 pl have a look.

FCM meets epigenetics, simple and fast. Good correlation with BCR::ABL1pos/like status and MRD. More global than molecular. https://t.co/OjaDeKnj96 @HematPgi @a_khadwal @ArihantDr #flowcytometry #Epigenetics #ALL

Come January 2025 and, we await the next edition of the Indian Myeloma Congress by IMAGe (@IndMyAcGp). We have an exciting lineup of lectures and interactions with Who's Who of Myeloma. Know your faculty. #TMCKolkata #IndianMyelomaCongress2025

@NabhajitM from PGIMER, Chandigarh, joins #FlowTCS2024 this year as an expert faculty in the workshop on baseline risk stratification in ALL. Come to #Mumbai next weekend and join the growing #flowcytometry community in India! @ICCS_Education @PrashantTembha1 @drkunalsehgal

Correlation of Bcl-2 and Mcl-1 expression in plasma cells by flow cytometry with cytogenetics in multiple myeloma. Much easier and objective than other methods. CG plus FCM to predict response to BH3 mimetcs. #myeloma #flowcytometry #MMsm #cytogenetics https://t.co/ABtQnGGEGS.

Have an interesting case you'd like to share at #FlowTCS2024, one of the best forums to discuss all things #flowcytometry? Reach out to @Gaurav_C42 and send it in, we'd love to hear from you! @ICCS_Education @LakshmiKoulmane @PrashantTembha1 @EsccaOfficial @ACScytometry

🚨 Join us for an exclusive webinar with Dr. Guilin Tang from MD Anderson Cancer Center on Optical Genome Mapping (OGM) in Hematological Disorders! 🚨 🗓️ Date: Aug 28, 2024 🕣 Time: 7:00 PM (IST) | 8:30 AM (Houston) 💻 Venue: Online Register via QR code. Hosted by Hemat PGI CHD

https://t.co/NYCqyOfGMn

PGIMER Chandigarh doctors pray for the victim and stand in solidarity with the doctors of RG Kar @MoHFW_INDIA @FA_PGI #BengalHorror #RGKarCollege

CLPDs are often easy to diagnose by #flowcytometry, but every now & then comes a case that throws us off course. How do we approach these systematically? What markers are essential in our panels? Find out these & more from the experts at the #CLPD workshop at #FlowTCS2024!

Missed it live? Watch our August Webinar: Clinical Aspects of Eosinophilia on YouTube now! https://t.co/38YtrhAjr0 @DrMMukherjee @KhouryMD @RossanaMelo5 @ArielMunitz

IES @EosinophilSoc in collaboration with #PGIMER and #ISHBT is organising this evening webinar on #eosinophilia with topics covering #Hematology & #immunology. Excellent speakers and moderators @DrPMPGI. Do register and attend!.

B Lineage Acute Lymphoblastic Leukemia with concurrent IGH and EPOR rearrangements – An Entity with Dismal Outcome #Hemepath @ArihantDr #MedTwitter